Abstract：Objective: To investigate the clinical efficacy and side effects of bortezomib combined with cyclophosphamide and dexamethasone in the treatment of multiple myeloma (MM). Methods: 70 cases of patients with multiple myeloma from October 2016 to October 2019 were divided into two groups according to the treatment, Bortezomib plus cyclophosphamide and dexamethasone group (cyclophosphamide group, n = 35) and bortezomib plus thalidomide and dexamethasone group (thalidomide group, n = 35). The clinical efficacy and toxicity of the two groups were statistically analyzed. Results: The deep response rate of cyclophosphamide group was 82.9% (29 / 35) significantly higher than that of thalidomide group 51.4% (18 / 35) (P<0.05). The incidence of side effects was 54.3% (19 / 35) in the cyclophosphamide group and 60.0%(21/35) in the thalidomide group. The difference between the two groups was not significant (P>0.05). Conclusion: The therapeutic effect of bortezomib combined with cyclophosphamide and dexamethasone is better than bortezomib combined with thalidomide and dexamethasone, and it will not increase the side effects of patients.
鲁俊, 朱熙君. 硼替佐米联合环磷酰胺及地塞米松治疗多发性骨髓瘤的临床疗效和毒副反应[J]. 河北医学, 2020, 26(4): 537-540.
LU Jun, ZHU Xijun. Efficacy and Side Effects of Bortezomib Combined with Cyclophosphamide and Dexamethasone in the Treatment of Multiple Myeloma. HeBei Med, 2020, 26(4): 537-540.
[1] 韩娜,李勇华,高飏,等.硼替佐米联合环磷酰胺及地塞米松方案治疗多发性骨髓瘤[J].实用医学杂志,2019,35(3):440~444,448. [2] 龚辉,陈姣,杜芳,等.BCD方案治疗初治多发性骨髓瘤患者疗效观察及预后分析[J].内科急危重症杂志,2019,25(5):397~400. [3] 李婉,马圣宇,黄静.地塞米松联合硼替佐米对老年多发性骨髓瘤的治疗效果[J].药物评价研究,2018,41(12):2313~2315,2348. [4] 谷景立,李娟,刘俊茹,等.大剂量美法仑与环磷酰胺、依托泊苷联合白消安预处理方案在多发性骨髓瘤自体造血干细胞移植中的比较[J].中华血液学杂志,2019,40(9):732~737. [5] 冶秀鹏,包慎,郭莹,等.7例少见类型多发性骨髓瘤及文献复习[J].重庆医学,2019,48(3):394~396. [6] 李娜,陈方.急性单核细胞白血病合并多发性骨髓瘤一例[J].国际输血及血液学杂志,2019,42(5):400~406. [7] 张怡安,庄静丽,王志梅,等.国产硼替佐米(昕泰)治疗初治多发性骨髓瘤的初步研究[J].中国临床医学,2019,26(2):224~228. [8] 张黎琴,田卫伟,王涛,等.VCD与VD方案治疗初诊多发性骨髓瘤患者效果及安全性分析[J].白血病·淋巴瘤,2018,27(8):453~458. [9] David Dingli, Sikander Ailawadhi, P. Leif Bergsagel, et al.Therapy for relapsed multiple myeloma: guidelines from the mayo stratification for myeloma and risk-adapted therapy[J]. Mayo Clin Proc,2017,92(4): 578~598.
2020, Vol. 26 
冀公网安备13080202000677号